An intense quest is ongoing for complementary tumour- or host-related predictive biomarkers in breast immuno-oncology. Among the upcoming biomarkers, quantity, immunophenotype and spatial distribution of tumour-infiltrating lymphocytes and other tumour microenvironment cells as well as immune gene signatures emerge as most promising and are being increasingly tested in clinical trials.
[ESMO Open]
7992332
{7992332:BBBBBBBB}
apa
50
1
166598
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
